KAPA Kairos Pharma, LTD.

NYSE kairospharma.com


$ 0.81 $ -0.01 (-1.72 %)    

Monday, 17-Nov-2025 10:17:42 EST
QQQ $ 609.20 $ 2.98 (0.49 %)
DIA $ 470.98 $ 0.12 (0.03 %)
SPY $ 671.25 $ 1.52 (0.23 %)
TLT $ 89.28 $ 0.20 (0.22 %)
GLD $ 374.37 $ 0.36 (0.1 %)
$ 0.8294
$ 0.83
$ 0.80 x 1,500
$ 0.81 x 1,500
$ 0.81 - $ 0.82
$ 0.40 - $ 3.25
428,082
na
16.76M
$ 0.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 04-15-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Interim efficacy analysis highlights potential value of combination therapy of ENV-105 and apalutamide following positive safet...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing resistance to current cance...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

Core News & Articles

Interim efficacy analysis highlights potential value of combination therapy of apalutamide and ENV105 following positive safety...

Core News & Articles

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today an...

Core News & Articles

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.05)...

Core News & Articles

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintains $9 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION